Genetic Test Evaluation

understanding how genetic tests impact patient management

Afirma Thyroid FNA Analysis (Veracyte)

October 19, 2017

In recent years, significant advances in understanding the genetic mechanisms of thyroid cancer have changed the way thyroid nodules are treated clinically. Several molecular targets have been associated with malignancy, including microRNA (miRNA), a noncoding endogenous form of RNA that helps regulate gene expression. Previous investigations have detected the dysregulation of miRNAs in malignant thyroid nodules, identifying the potential role of miRNAs in differentiating benign thyroid nodules from malignant ones. The Afirma Thyroid FNA Analysis is a diagnostic service that includes thyroid-specialized cytopathology and gene expression testing for the analysis of FNA thyroid nodule biopsies. This report examines the published evidence regarding the Afirma Thyroid FNA Analysis.